SOSV

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Ostoform Limited is a medical device company based in Dublin, Ireland, specializing in products designed to manage skin complications for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform has developed patented technologies aimed at enhancing ostomy skin health. Its flagship products include a mouldable seal that fits securely around the stoma, preventing corrosive output from contacting the skin, and FLOWASSIST, which directs stoma output away from the skin to minimize irritation and swelling. By addressing these significant challenges faced by ostomy patients, Ostoform aims to improve comfort and overall quality of life, positioning itself as a potential leader in the global ostomy care market.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.

Serene Sleep is a medical technology company that focuses on improving sleep quality by addressing snoring and sleep apnea. It develops and offers a non-invasive, targeted treatment procedure using palatal implants, designed to reduce disruptive snoring and enhance overall sleep for both the individual and their partner.

Machine Medicine Technologies Ltd, established in 2017 and based in London, UK, specializes in developing artificial intelligence-driven solutions for healthcare. The company's core product, KELVIN-PD, employs computer vision and pose estimation to objectively measure and analyze movement disorders, such as tremors and bradykinesia, in Parkinson's disease patients using simple video clips. This platform offers secure data management, accessibility from various devices, and affordability, making it a valuable tool for researchers and clinicians.

Exosomm is an innovative foodtech start-up focused on developing nutritional solutions derived from natural milk exosomes. The company was founded based on research from Hadassah Medical Center, led by Prof. Reif's team. Exosomm's flagship product is a specialized food formula designed for patients suffering from inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. This product utilizes a patented active anti-inflammatory ingredient sourced from milk exosomes, which are isolated using a natural and environmentally friendly process. By targeting health and immunity, Exosomm aims to provide effective solutions for individuals with specific dietary needs.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

heXem bio specializes in recording solutions for the early development of humans for longevity.

Zhenshi Medical is a medical device company that specializes in lung puncture medical robots for diagnosing and treating lung cancer.

DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in the development of an innovative artificial intelligence-powered magnetic resonance imaging (MRI) system. The company's technology aims to significantly reduce the cost, size, and weight of traditional MRI machines, thereby enhancing accessibility to medical imaging for patients worldwide. By utilizing generative topological design for its hardware and deep learning techniques for image processing, DeepSpin's MRI system seeks to make advanced medical imaging available in a variety of previously underserved healthcare settings. This approach not only aims to improve patient care but also to democratize access to essential medical diagnostics globally.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

GlowDx, established in 2015 and headquartered in Midleton, Ireland, specializes in developing point-of-care diagnostic solutions. The company aims to decentralize molecular testing, enabling local access to improve clinical outcomes and reduce economic burden for patients, particularly in tropical disease diagnosis. GlowDx achieves this by employing novel molecular technology tailored for efficient, on-site diagnostics.

EIO Diagnostics Inc. is a Canadian company specializing in udder health technology for dairy farming. Founded in 2017 and based in Duncan, it develops the FirstLook Mastitis detection system, which aims to prevent mastitis infections in dairy animals. The system employs a multispectral sensor installed at the entrance of the milk parlor to capture images of the udder as cows enter, enabling early detection of infection indicators through advanced infrared image analysis and computer vision. This technology automates the screening process, allowing farmers to monitor udder health efficiently, reduce labor costs, and enhance milk quality.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin through precision fermentation technology. This innovative approach allows the company to manufacture melanin at scale and at an affordable cost, making it suitable for diverse applications across various industries. Avisa Myko's melanin serves multiple purposes, including protection against ionizing radiation and use in electricity generation. Its high-purity melanin is easily redissolved, facilitating incorporation into products such as cosmetics, biomedicine, organic semiconductors, biosensors, latex products, and fabrics. The company is also developing a prototype sunscreen that utilizes melanin as an ultraviolet blocker, distinguishing itself by avoiding traditional chemical or mineral UV blockers. Through its patented technology, Avisa Myko aims to contribute to better health and environmental sustainability.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company focuses on developing innovative healthcare solutions to assist mechanically ventilated patients in weaning off ventilators more efficiently. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, thereby mitigating the risks of diaphragm dysfunction associated with prolonged mechanical ventilation. By enhancing the weaning process, XN Health aims to improve patient outcomes and facilitate recovery in critical care settings.

Chronus Health, Inc. is a medical technology company that specializes in developing a portable diagnostic device capable of delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in Mountain View, California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time diagnostic capabilities. This innovative system allows for the delivery of lab results within minutes, significantly enhancing the speed of diagnosis and improving patient outcomes by enabling timely and informed treatment decisions.

Verdex Technologies is a company based in Chesterfield, Virginia, specializing in the design, patenting, and licensing of non-toxic nanofiber producing equipment for filtration and biomedical applications. Founded in 2011, Verdex focuses on mass-producing high-quality nanofibers using proprietary green technology, which avoids toxic solvents or petroleum products. The company's innovative process allows nano-fibers to be functionalized by impregnating them with other nano-sized ingredients, enhancing the effectiveness of various products such as water filters and face masks. Verdex's scalable technology platform enables the cost-effective production of nanofiber materials from a wide range of natural and synthetic polymers, making it commercially feasible for numerous applications including engine filters, liquid filters, industrial air filters, and technical textiles.

Lura Health is a pioneering company that has developed a non-invasive continuous health monitoring platform utilizing saliva as a diagnostic fluid. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company focuses on chronic disease management, targeting conditions such as heart disease, chronic kidney disease, diabetes, and tooth decay. Lura Health's innovative sensors are designed to be integrated into patient-friendly orthodontic devices, including removable retainers and fixed brackets. These sensors continuously monitor oral acidity and other analytes in saliva, automatically transmitting valuable health data to a mobile application. This approach empowers users to track key diagnostic metrics within their oral environment, facilitating improved personal health management and potentially enhancing clinical outcomes.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Hypercell Technologies specializes in developing innovative tools for controlling infectious diseases in animals. The company's core focus is on creating rapid, accurate diagnostic tools using molecular biology techniques, which enable veterinarians to detect and manage infections swiftly. Additionally, Hypercell develops monoclonal antibodies designed to proactively control viruses in production animal reservoirs, aiming to prevent potential zoonotic disease outbreaks in humans by addressing the source in animals.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

LightHearted AI is a company that specializes in developing an AI-driven remote cardiovascular diagnostics tool aimed at improving the detection of heart conditions. This medical device is designed to deliver rapid, precise, and cost-effective assessments, addressing the critical need to prevent heart-related deaths. By leveraging advanced technology, LightHearted AI enhances the capabilities of healthcare professionals, allowing for faster and more accurate diagnostic procedures compared to traditional methods. The company's innovation seeks to transform cardiac care, ultimately contributing to better treatment outcomes for patients.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin through precision fermentation technology. This innovative approach allows the company to manufacture melanin at scale and at an affordable cost, making it suitable for diverse applications across various industries. Avisa Myko's melanin serves multiple purposes, including protection against ionizing radiation and use in electricity generation. Its high-purity melanin is easily redissolved, facilitating incorporation into products such as cosmetics, biomedicine, organic semiconductors, biosensors, latex products, and fabrics. The company is also developing a prototype sunscreen that utilizes melanin as an ultraviolet blocker, distinguishing itself by avoiding traditional chemical or mineral UV blockers. Through its patented technology, Avisa Myko aims to contribute to better health and environmental sustainability.

Verdex Technologies is a company based in Chesterfield, Virginia, specializing in the design, patenting, and licensing of non-toxic nanofiber producing equipment for filtration and biomedical applications. Founded in 2011, Verdex focuses on mass-producing high-quality nanofibers using proprietary green technology, which avoids toxic solvents or petroleum products. The company's innovative process allows nano-fibers to be functionalized by impregnating them with other nano-sized ingredients, enhancing the effectiveness of various products such as water filters and face masks. Verdex's scalable technology platform enables the cost-effective production of nanofiber materials from a wide range of natural and synthetic polymers, making it commercially feasible for numerous applications including engine filters, liquid filters, industrial air filters, and technical textiles.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

TippingPoint Biosciences is focused on developing innovative therapeutics that address diseases caused by defects in DNA packaging, with an emphasis on conditions such as cancer and neurodegenerative disorders. Utilizing a specialized drug discovery platform, the company aims to identify new treatment options that specifically target unique genome packaging states associated with various diseases. This approach not only facilitates the treatment of cancer but also holds potential for advancing stem cell therapies by correcting dysfunctional genome packaging. Through its research and development efforts, TippingPoint Biosciences seeks to provide effective solutions for complex medical challenges.

Karma Biotechnologies, Inc. is a biotechnology company based in Los Angeles, California, focused on developing innovative therapies for autoimmune diseases, allergies, and food sensitivities. Established in 2019, the company has introduced Xavines, a precision immunotherapy platform aimed at addressing the critical need for antigen-specific treatments that target only the harmful immune cells responsible for these conditions. Unlike conventional approaches that rely on general immune suppression, Karma's technology is designed to promote antigen-specific immune tolerance in vivo. By leveraging expertise in immunology and lipid nanoparticle engineering, the company aims to create off-the-shelf therapeutics that effectively switch off the rogue immune responses associated with autoimmunity and related disorders, thereby enhancing the treatment landscape for these conditions.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative therapies for cancer treatment. The company specializes in creating Pannexin 1 channel (Panx1) blockers, which represent a novel class of drugs aimed at inhibiting multiple pathways that contribute to the growth, spread, and survival of cancer cells. Pannex Therapeutics' therapies are designed to provide high specificity for cancer cells, ensuring effective treatment while minimizing side effects and the risk of addiction. By advancing these promising treatments, the company seeks to transform cancer therapy and improve patient outcomes.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles engineered to signal through validated targets. Diadem's therapeutic platform aims to treat a variety of chronic inflammatory conditions, autoimmune diseases, and cancers. By focusing on the genetic engineering, manufacturing, and purification of these exosomes, Diadem provides innovative solutions for clinicians to effectively address immunopathologies and improve patient outcomes.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Care Constitution is a telehealth service company that provides a platform for clients to conduct health checkups online. The company focuses on assisting healthcare professionals by integrating AI technology into its services, which enhances diagnostic testing and supports accurate diagnoses. By offering a standard of care in medicine, Care Constitution aims to deliver objective, reproducible, and quantitative healthcare assessments, thereby improving the overall quality of medical care.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

AuraSense is a company that leverages artificial intelligence and automation to enhance neurological examinations, converting subjective assessments into quantifiable data. By merging video game technology with practical medical procedures, AuraSense develops digital touch technology that enables the early detection of limb damage and facilitates remote physical examinations for various diseases. This innovative approach allows neurologists to accurately evaluate patients' cognitive and physical health, leading to personalized treatment plans tailored to individual needs. Through its technology, AuraSense aims to improve health outcomes and ensure that patients receive effective, data-driven care.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

Kolibri is a biotechnology company focused on revolutionizing large-scale cell culture to enhance accessibility and affordability in cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that employs advanced techniques in acoustics and biology, enabling its bioreactors to achieve a 90-fold increase in cell yield while significantly reducing production costs by up to 50 times. Kolibri's innovative bioreactors are designed to facilitate the efficient growth of cells at scale, thereby supporting partners in drug development and providing critical solutions for unlocking patient access to gene therapies and next-generation vaccines. Through its technological advancements, Kolibri aims to address key challenges in the bioproduction of biologics.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

Midoconline is a technology company focused on improving quality of life through medical and wellness services. It has developed a telehealth platform that facilitates video-based consultations between patients and healthcare professionals. Through its mobile application, Midoconline enables users to connect with doctors for remote consultations regarding non-emergency medical issues, thereby enhancing access to healthcare services.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Free to Feed is a company focused on enhancing breastfeeding experiences by providing solutions for detecting food allergens in breast milk. It offers an innovative over-the-counter allergen test that empowers breastfeeding mothers to identify various food proteins in their milk, which is crucial for those concerned about potential infant food allergies or intolerances. The company’s patented testing kits, combined with a mobile application, allow mothers to document the presence of allergens, the timing of milk expression, and any symptoms their infants may exhibit. This comprehensive data collection aids medical professionals in diagnosing and managing food allergies effectively. With a growing recognition of the importance of early allergen introduction to mitigate future allergies, Free to Feed supports parents in navigating these complexities with tailored counseling and technology, ensuring they can confidently meet their breastfeeding goals while safeguarding their infants' health.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

ChektAhora is a Latin American company specializing in at-home testing kits for sexually transmitted infections (STIs). Their platform offers confidential, convenient, and pain-free testing solutions, utilizing PCR tests to identify STIs and other infectious diseases like influenza and COVID-19. The company aims to provide accessible healthcare services directly to customers' homes or offices.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Verdex Technologies is a company based in Chesterfield, Virginia, specializing in the design, patenting, and licensing of non-toxic nanofiber producing equipment for filtration and biomedical applications. Founded in 2011, Verdex focuses on mass-producing high-quality nanofibers using proprietary green technology, which avoids toxic solvents or petroleum products. The company's innovative process allows nano-fibers to be functionalized by impregnating them with other nano-sized ingredients, enhancing the effectiveness of various products such as water filters and face masks. Verdex's scalable technology platform enables the cost-effective production of nanofiber materials from a wide range of natural and synthetic polymers, making it commercially feasible for numerous applications including engine filters, liquid filters, industrial air filters, and technical textiles.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.

RxDiet is a company that specializes in nutritional guidance by leveraging artificial intelligence and automation to enhance health outcomes. It has developed a platform that offers personalized meal plans based on individual cultural and lifestyle preferences. By partnering with national food retailers, RxDiet provides users with access to fresh groceries, facilitating healthier dietary choices at reduced costs. Additionally, the company collaborates with major health payers and employers to achieve significant clinical results and cost savings, promoting the concept of "food as medicine" within the healthcare landscape.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Machine Medicine Technologies Ltd, established in 2017 and based in London, UK, specializes in developing artificial intelligence-driven solutions for healthcare. The company's core product, KELVIN-PD, employs computer vision and pose estimation to objectively measure and analyze movement disorders, such as tremors and bradykinesia, in Parkinson's disease patients using simple video clips. This platform offers secure data management, accessibility from various devices, and affordability, making it a valuable tool for researchers and clinicians.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Chronos DX is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics within the healthcare sector. The company is known for its innovative bioassay technology, which is designed for diagnostics, drug screening, and development. Chronos DX focuses on creating high-performance, low-cost, and scalable technology capable of detecting a variety of biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This technology provides medical professionals with a platform for in-line and in vivo monitoring of biomarkers, enhancing the capabilities of diagnostics and drug development in medical practice.

GlowDx, established in 2015 and headquartered in Midleton, Ireland, specializes in developing point-of-care diagnostic solutions. The company aims to decentralize molecular testing, enabling local access to improve clinical outcomes and reduce economic burden for patients, particularly in tropical disease diagnosis. GlowDx achieves this by employing novel molecular technology tailored for efficient, on-site diagnostics.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. It operates a proprietary drug discovery platform that utilizes synthetic biology to expand the druggable proteome, focusing on therapeutic applications in oncology and rare diseases. The platform employs empirical intracellular selection to identify and design compounds that can modulate protein interactions, either disrupting specific protein-protein interactions or facilitating the targeted degradation of proteins through the recruitment of E3 ubiquitin ligases. SyntheX's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that evade chemotherapy through homologous recombination. The company identifies drug targets by analyzing clinical, evolutionary, phenotypic, and structural data, and it maintains both internal oncology projects and collaborative discovery initiatives.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

EIO Diagnostics Inc. is a Canadian company specializing in udder health technology for dairy farming. Founded in 2017 and based in Duncan, it develops the FirstLook Mastitis detection system, which aims to prevent mastitis infections in dairy animals. The system employs a multispectral sensor installed at the entrance of the milk parlor to capture images of the udder as cows enter, enabling early detection of infection indicators through advanced infrared image analysis and computer vision. This technology automates the screening process, allowing farmers to monitor udder health efficiently, reduce labor costs, and enhance milk quality.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative therapies for cancer treatment. The company specializes in creating Pannexin 1 channel (Panx1) blockers, which represent a novel class of drugs aimed at inhibiting multiple pathways that contribute to the growth, spread, and survival of cancer cells. Pannex Therapeutics' therapies are designed to provide high specificity for cancer cells, ensuring effective treatment while minimizing side effects and the risk of addiction. By advancing these promising treatments, the company seeks to transform cancer therapy and improve patient outcomes.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Aksense is a biotechnology company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. It has created the first portable rapid infection diagnostic biosensor designed to enhance the quality of care in healthcare settings. Aksense aims to improve antibiotic prescribing practices and public health outcomes by enabling early detection and treatment of infections. Its technology facilitates faster recovery for patients through cost-effective molecular testing, ultimately reducing the spread of infections and improving overall patient outcomes.

AnimalBiome specializes in personalized nutrition services that focus on enhancing the gut health of dogs and cats through microbiome science. The company offers microbiome tests that assess the unique gut microbiota of individual pets, providing insights that inform tailored nutrition recommendations. Additionally, AnimalBiome develops restorative supplements made from material sourced from healthy animals, allowing for the introduction of beneficial microbes to help restore balance in the gut microbiome. By leveraging advanced diagnostic tools, including DNA sequencing, AnimalBiome enables pet owners to better understand their pets' gut health, ultimately contributing to improved well-being and a healthier lifestyle for their animals.

Portable Diagnostic Systems, established in August 2019, specializes in developing a microfluidics-based drug testing platform tailored for law enforcement agencies. Their innovative solution enables swift and accurate roadside saliva tests, reducing the need for guesswork during impaired driving traffic stops. The company's platform leverages salivary diagnostics, antibody engineering, and microfluidics to deliver precise results from small samples, thereby minimizing false positives and enhancing public safety.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. The company focuses on improving maternal health outcomes by developing safe, affordable, and accessible home-based early detection tests for complications during pregnancy. One of its key products is a low-cost, reliable preeclampsia detection strip, which enables expectant mothers to self-screen for this serious condition. By facilitating early detection, Kalia Health aims to empower women to seek timely medical intervention, ultimately reducing the risks associated with preeclampsia and enhancing maternal health.

Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.

Tesarakt is a New York City-based company founded in 2022 that specializes in developing predictive artificial intelligence technology for brain care. The company focuses on enhancing neuro-diagnosis by employing advanced artificial intelligence and machine learning techniques. Tesarakt utilizes a comprehensive database of conventional MRI scans to improve the predictive capabilities of medical professionals, enabling earlier detection of neurological disorders such as Parkinson's disease and Alzheimer's disease, often before the onset of initial symptoms. Through its innovative approach, Tesarakt aims to transform the way neurological conditions are diagnosed and managed.

Tesarakt is a New York City-based company founded in 2022 that specializes in developing predictive artificial intelligence technology for brain care. The company focuses on enhancing neuro-diagnosis by employing advanced artificial intelligence and machine learning techniques. Tesarakt utilizes a comprehensive database of conventional MRI scans to improve the predictive capabilities of medical professionals, enabling earlier detection of neurological disorders such as Parkinson's disease and Alzheimer's disease, often before the onset of initial symptoms. Through its innovative approach, Tesarakt aims to transform the way neurological conditions are diagnosed and managed.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

FoodMarble is a company focused on addressing the needs of individuals suffering from digestive issues, a challenge that affects nearly one billion people worldwide. It has developed the AIRE device, a personal breath analyzer that assists users in identifying foods that align with their unique digestive systems. By utilizing techniques found in gastroenterology, AIRE enables real-time tracking of digestive responses to various foods through a handheld, affordable device and an accompanying application. This innovative approach allows users to craft personalized diets that can alleviate discomfort and improve overall well-being. FoodMarble has garnered significant interest, with over $500,000 in pre-orders, and aims to create a comprehensive dataset to enhance understanding of digestive health.

PhableCare creates an ecosystem of patients, doctors, hospitals, health devices, insurance, and patient care service providers. In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring.